Weekly Issue — 2025-12-14

The study, led by a team at Siriraj Hospital in Bangkok, followed nearly 5,000 adults without diabetes for a median of 8.8 years and used a machine-learning technique called k-means clustering to sort them by six routine variables: age, BMI, fasting glucose, HbA1c, HDL cholesterol and ALT (a liver enzyme). What emerged were six distinct subphenotypes with meaningfully different futures — not a smooth gradient from "a little high" to "a lot high," but discrete patterns that behave differently over time.

That distinction matters. If pre-diabetes is really a family of conditions, then a person whose HbA1c sits at 6.0% because they are lean, older and slightly insulin-resistant is being asked to follow the same advice as someone whose 6.0% comes packaged with obesity, a fatty liver and low HDL. The first person's risk curve and the second person's risk curve, this paper suggests, are not the same shape at all.

The researchers labeled their six groups descriptively. Cluster 1 was a low-risk group — younger, leaner, with relatively clean labs. Cluster 2 was older adults with mild dysglycemia. Cluster 3 combined severe dysglycemia with obesity. Cluster 4 had milder glucose elevations but obesity. Cluster 5 was the "severe dysmetabolic obese" group, where glucose, lipids and liver markers were all off at once. Cluster 6 was older adults with severe dysglycemia — and it carried the highest risk profile of all, with significantly elevated rates of macrovascular events compared with the others, according to the Siriraj cohort analysis.

What is striking is not just that the clusters differ on paper, but that they diverged in real outcomes over nearly nine years of follow-up. Some groups progressed to type 2 diabetes at substantially higher rates. Others were more likely to experience large-vessel complications — the kind that drive heart attacks and strokes. The conventional cut-points (fasting glucose 100–125 mg/dL, HbA1c 5.7–6.4%) lumped all of these people together. The clustering pulled them apart.

Subtyping is having a moment in metabolic medicine. Earlier European work famously split adult-onset diabetes into roughly five clusters with different complication profiles, and researchers have been chasing the same logic upstream into pre-diabetes ever since. The new Thai analysis is part of that wave: an attempt to replace a binary label with a map.

For readers who already track their own data — CGM curves, fasting glucose, an annual HbA1c, a lipid panel — the practical implication is subtle but real. A single number, viewed in isolation, is a weak predictor. The combination of numbers, viewed together, may be a much stronger one. A mildly elevated HbA1c in someone with a healthy BMI, normal liver enzymes and high HDL is a very different signal from the same HbA1c in someone whose ALT is creeping up and whose HDL is low.

It is worth being honest about what this study is and isn't. It is a single-center cohort from one hospital in Bangkok, with a participant pool whose average age was around 60 and which skewed slightly female. The clusters were generated using a statistical technique that finds patterns in this dataset; whether the same six groups reappear in, say, a younger European or American cohort is an open question. The authors themselves frame the work as a step toward more granular risk stratification, not a finished clinical tool.

That is also why our editors rated the evidence here as moderate rather than strong. The signal is real and the methodology is reasonable, but the clusters need to be reproduced in other populations before any clinician — or any wellness writer — should start telling people which "type" of pre-diabetes they have.

You do not need to wait for personalized pre-diabetes care to arrive to start thinking like the researchers behind it. The variables they chose are not exotic; they are the six lines that already appear on most routine bloodwork. Looking at them as a pattern — rather than scanning for a single red flag — is closer to how this research suggests risk actually clusters.

If your fasting glucose or HbA1c has nudged into the pre-diabetes range, the genuinely useful next step is not to self-sort into a cluster but to bring the full panel to a clinician who can interpret it in context. Age, body composition, family history, liver markers and lipids all carry information that a glucose number alone does not.

Personalized metabolic care is not here yet. But the direction of travel is clear, and it is away from the blunt yes/no of "pre-diabetes" and toward something more like a weather forecast: a probability, a pattern, and a set of choices calibrated to your specific sky. The six-cluster framework is a draft of that forecast — early, imperfect, and genuinely interesting.

The study, a PRISMA-guided systematic review and meta-analysis published in Frontiers in Endocrinology, pooled 23 studies and 179 cohorts — more than 65,000 people with type 1 diabetes (T1D) and over 139 million with type 2 diabetes (T2D) — to estimate average life expectancy across groups. It's the most comprehensive benchmark we have so far, and it gives metabolic health a clearer place in the longevity conversation: a central one, but not a deterministic one. The researchers used random-effects models, reported wide prediction intervals, and were transparent about heterogeneity, which is the polite scientific way of saying: these are averages drawn from very different populations, and your individual story is not a line on this graph.

Here is what they found, in plain numbers. Average life expectancy was shortest among adults with T1D — roughly 65.1 years in men and 68.3 years in women. For T2D, the pooled estimate was 74.3 years in men, with the women's figure in the same broad range. Those numbers sit below typical non-diabetic life expectancy in the same cohorts, which is the gap the authors set out to quantify as years of potential life lost. The differences are real and meaningful — but the prediction intervals are wide (the T1D men's interval, for instance, stretched from the early 40s into the late 80s), which tells us care, context and era matter enormously.

Diabetes shortens average life expectancy mainly through its downstream effects: cardiovascular disease, kidney disease, and the slow erosion of small blood vessels that supply nerves, eyes and organs. The mechanism, simply put, is that chronically elevated blood glucose and the insulin-handling problems behind it stress the vascular system over decades. The newer the cohort and the better the care, generally, the smaller the gap — which is part of why the authors did meta-regression on cohort year. The body of evidence here is solid in design but moderate in certainty: averages from observational cohorts, not a controlled experiment on your future.

For parents reading this on four hours of sleep, the takeaway isn't a personalised prognosis. It's a frame. Metabolic health — how your body manages glucose, fat, blood pressure and weight over years — is one of the biggest modifiable inputs to how long, and how well, you live. That's a reason for attention, not alarm.

If you have diabetes, or a family history, or a recent borderline lab result, the honest read is this: the gap exists, and it is also narrower than it used to be in many settings. The meta-analysis was designed to compare across regions and eras, and the authors' decision to publish prediction intervals — not just confidence intervals — is a quiet act of intellectual honesty. It says: on average, here is the picture; for any one person, the range is wide, and what fills it includes things like blood pressure control, kidney function, smoking, sleep, movement and access to care.

None of that is a prescription. A clinician who knows your history is the right person for that conversation, especially if you're pregnant, postpartum, or managing T1D or T2D alongside a young family. What an article like this can offer is perspective: the smallest useful step usually beats the perfect plan you can't start this week.

What I find quietly hopeful about this paper is not the averages themselves but the structure beneath them. The fact that newer cohorts tend to do better suggests that the gap is responsive — to medication, to monitoring, to the unglamorous daily levers of sleep, movement and food. None of that is news. But having a clearer number to push against makes the work feel less abstract, especially when the work in question is fitting a walk in between nap time and dinner.

The headline isn't that diabetes steals a fixed number of years. It's that metabolic health is worth paying attention to early, gently and consistently — and that the science is finally catching up to tell us, with reasonable confidence, just how much that attention may be worth.

The first is a systematic review and meta-analysis of 38 studies in patients with overweight or obesity, pooling cardiovascular outcomes and adverse events. The second is an omics-level mechanistic review that maps the proteomic and metabolomic fingerprints semaglutide leaves behind — the molecular trail that may explain why the outcome numbers move the way they do. Read together, they let us answer a more useful question than "does it work?": what, specifically, does it change, and at what cost?

Start with what a 40-year-old actually cares about: am I less likely to have a heart attack, end up in a hospital bed, or die early? The pooled analysis reports relative-risk reductions across exactly those endpoints. Heart-failure hospitalization showed the largest signal, with a relative risk of 0.24 (95% CI 0.12–0.57) across two studies and roughly 1,045 participants — a small pool, so treat the magnitude with appropriate caution. Cardiovascular death came in at RR 0.83 (0.71–0.98) and all-cause death at RR 0.79 (0.70–0.89), both drawn from a much larger combined sample of about 24,000 people. Non-fatal myocardial infarction landed at RR 0.76 (0.66–0.88), and coronary revascularization at RR 0.76 (0.69–0.85).

Stroke is the asterisk. The reduction — RR 0.65 (0.44–0.97) — reached significance specifically in the diabetes subgroup, not across the broader overweight/obesity population. That's a meaningful distinction. If your interest in semaglutide is metabolic optimization rather than diabetes management, the stroke data don't yet support the same confidence as the cardiac endpoints.

The convenient explanation for any cardiovascular benefit in an obesity drug is: people lost weight, and weight loss is cardioprotective. True, and probably part of the story. But the omics review argues the picture is richer than that. Using mass spectrometry and NMR-derived proteomic and metabolomic signatures, the analysis traces semaglutide's effects across insulin secretion, lipid metabolism, body-weight regulation and — importantly — anti-inflammatory pathways. Chronic low-grade inflammation is one of the more credible non-LDL drivers of atherosclerotic disease, and a drug that nudges those markers downward has a plausible mechanism to reduce events even before the scale moves much.

That mechanistic plurality matters when you're trying to decide what a result means. If benefit ran purely through weight loss, you'd expect outcomes to track tightly with pounds dropped. If anti-inflammatory and lipid-handling effects contribute independently, the calculus for someone who is, say, 15 pounds over their target rather than 50 starts to look different — though the trial evidence in that leaner subgroup is thinner.

Adverse events were the other half of the meta-analysis, and the pooled relative-risk of side effects was significantly elevated for nearly every category examined. The exception worth noting: discontinuation rates on oral semaglutide didn't reach significance. Constipation frequency didn't differ between administration routes or between oral doses. None of this is exotic — GI complaints have always been the dominant tolerability story for GLP-1s — but it's a useful reminder that the cardioprotective signal comes packaged with real day-to-day costs that show up in adherence data.

The route comparison is worth lingering on. The analysis found a subgroup difference (p = 0.05) favoring subcutaneous over oral administration on certain outcomes. That's a borderline signal, not a verdict — but it lines up with what's long been suspected about the pharmacokinetic differences between weekly injection and daily oral dosing.

If you're in the meta-analysis's actual population — overweight or obese, with elevated cardiometabolic risk — the data now support a more confident conversation with a clinician about cardiovascular benefit, not just weight. The mortality and MI signals are drawn from samples large enough to take seriously, even at moderate evidence strength.

If you're closer to the optimizer archetype — body composition you're proud of, training dialed in, hunting for an edge — the honest read is that the trial populations don't look like you, and the magnitude of any cardiovascular dividend in a leaner, fitter subgroup is genuinely unknown. The mechanistic plausibility is there. The outcome data aren't.

Either way, this is a clinician conversation, not a checkout-cart decision. The cardiovascular case for semaglutide is the strongest it has ever been. It is also still being written.